Overview
flowchart TD
companies_ad_neuroprotective_p["AD Neuroprotective Peptide and Peptide-Based The"]
style companies_ad_neuroprotective_p fill:#4fc3f7,stroke:#333,color:#000
companies_ad_neuropr_0["Key Companies and Programs"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_0
style companies_ad_neuropr_0 fill:#81c784,stroke:#333,color:#000
companies_ad_neuropr_1["Neurotrope Bioscience Acumen Pharmaceuticals"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_1
style companies_ad_neuropr_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_neuropr_2["Cognition Therapeutics"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_2
style companies_ad_neuropr_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_neuropr_3["Spinogenix"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_3
style companies_ad_neuropr_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_neuropr_4["Prothelia"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_4
style companies_ad_neuropr_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_neuropr_5["Alector"]
companies_ad_neuroprotective_p -->|"includes"| companies_ad_neuropr_5
style companies_ad_neuropr_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Neuroprotective peptides and peptide-based therapies represent a promising class of disease-modifying approaches for Alzheimer's disease (AD). These short amino acid sequences (typically 5-40 residues) are derived from endogenous neuropeptides or engineered synthetically to protect neurons from amyloid toxicity, oxidative stress, excitotoxicity, and neuroinflammation["@craik2013"].
Unlike small molecule drugs, peptides can interact with larger surface areas on target proteins, enabling more specific modulation of protein-protein interactions that are difficult to target with traditional pharmaceuticals. The therapeutic rationale for neuroprotective peptides in AD rests on several key observations: peptides can cross the blood-brain barrier with appropriate modifications; they target multiple pathways involved in neurodegeneration simultaneously; and several have demonstrated favorable safety profiles in clinical trials["@Brimson2019"].
This category page consolidates companies developing neuroprotective peptide therapeutics for AD, including:
- Peptide fragments derived from endogenous proteins
- Synthetic peptide analogs designed to enhance neuroprotection
- Peptide-based approaches targeting amyloid-beta toxicity
- Synaptic protection peptides
- Brain-derived neurotrophic factor (BDNF) mimetics
Key Companies and Programs
Neurotrope Bioscience (Acumen Pharmaceuticals)
Neurotrope Bioscience (acquired by Acumen Pharmaceuticals) focused on developing bryostatin-based therapeutics for Alzheimer's disease. The company's lead candidate, bryostatin-1 (also known as Altumab or NRO-1), is a protein kinase C (PKC) activator that promotes synaptic plasticity and neurotrophic factor expression.
- Focus: Neurotrophic factor delivery and synaptic plasticity
- Lead Candidate: Bryostatin-1
- Mechanism: PKC activation promotes synaptogenesis, enhances long-term potentiation (LTP), and protects against excitotoxicity. Bryostatin has been shown to increase synaptic protein expression, including synapsin I and PSD-95, in preclinical models
- Stage: Phase 2 completed
- ClinicalTrials.gov: NCT04594060
- Related Page: [Acumen Pharmaceuticals](/companies/acumen-pharmaceuticals)
Cognition Therapeutics
Cognition Therapeutics is focused on developing small molecule therapeutics targeting sigma-2 receptors to treat Alzheimer's disease and other protein aggregation disorders. The company's lead candidate, CT-1812 (ELND005), is a novel sigma-2 receptor modulator that has progressed through Phase 1 and Phase 2 clinical trials.
- Focus: Synaptic protection and function restoration
- Lead Candidate: CT-1812 (sigma-2 receptor modulator)
- Mechanism: CT-1812 targets the sigma-2 receptor complex, which is involved in cellular stress response and cholesterol homeostasis. The compound displaces toxic oligomers from synaptic membranes, thereby protecting synaptic integrity and function
- Stage: Phase 1-2 completed
- ClinicalTrials.gov: NCT05531695
Spinogenix
Spinogenix is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics targeting synaptic regeneration in Alzheimer's disease and other neurodegenerative conditions.
- Focus: Synaptic repair and cognitive restoration
- Lead Candidate: SPG-302
- Mechanism: Promotes synaptogenesis and dendritic spine formation through novel mechanisms
- Stage: Phase 1 ongoing
- Related Page: [Spinogenix](/companies/spinogenix)
Prothelia
Prothelia is focused on developing protein replacement therapies and neuroprotective molecules for neurodegenerative diseases.
- Focus: Protein replacement and neuroprotection
- Mechanism: Development of neurotrophic factor mimetics
- Stage: Preclinical/IND-enabling
Alector
Alector is developing immune-neurology therapeutics that harness the brain's immune system to treat neurodegenerative diseases. While primarily focused on TREM2 and other immune targets, their approach includes neuroprotective mechanisms.
- Focus: Immune-mediated neuroprotection
- Lead Candidates: AL001, AL002 (TREM2 agonists)
- Stage: Phase 2/3
Neuraly is a clinical-stage biopharmaceutical company exclusively focused on developing GLP-1 receptor agonists for neurodegenerative diseases, including peptide-based approaches.
- Focus: GLP-1 based neuroprotection
- Lead Candidate: NLY01
- Stage: Phase 1-2
- Related Page: [Neuraly](/companies/neuraly)
Peptide Classes in Development
BDNF-Derived Peptides
Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin that supports neuronal survival, synaptic plasticity, and cognitive function. BDNF and its derivatives have been extensively studied for neuroprotective applications:
| Company | Peptide | Target | Stage |
|---------|---------|--------|-------|
| Various | BDNF 1-28 | TrkB agonist | Preclinical |
| Various | BDNF loop 1 peptide | TrkB agonist | Preclinical |
| Neurotrope | Bryostatin-1 | PKC activator | Phase 2 |
NAP (NAPVSIPQ) Peptides
NAP (NAPVSIPQ) is an 8-amino acid peptide derived from activity-dependent neuroprotective protein (ADNP). It binds to tubulin and promotes microtubule stabilization.
| Company | Product | Stage |
|---------|---------|-------|
| Formerly Allon Therapeutics | Davunetide (AL-108) | Phase 2 |
Anti-Amyloid Peptides
Peptides designed to prevent or disrupt amyloid-beta aggregation:
| Company | Product | Mechanism | Stage |
|---------|---------|-----------|-------|
| Various | Aβ aggregation inhibitors | Beta-sheet blockers | Preclinical |
Sigma-2 Receptor Modulators
Small molecule/peptide modulators that protect synapses from toxic oligomers:
| Company | Product | Mechanism | Stage |
|---------|---------|-----------|-------|
| Cognition Therapeutics | CT-1812 | Sigma-2 modulation | Phase 2 |
Pipeline Overview
| Company | Lead Program | Mechanism | Indication | Stage |
|---------|---------------|-----------|------------|-------|
| Acumen/NBC | Bryostatin | PKC activation | AD | Phase 2 |
| Cognition Therapeutics | CT-1812 | Sigma-2 | AD | Phase 2 |
| Spinogenix | SPG-302 | Synaptogenesis | AD | Phase 1 |
| Neuraly | NLY01 | GLP-1 | AD/PD | Phase 1-2 |
| Alector | AL001/002 | TREM2 | AD | Phase 2/3 |
Related Pages
- [Neuroprotective Peptides](/therapeutics/neuroprotective-peptides)](/therapeutics)
- [Peptide-Based Therapeutics](/therapeutics/peptide-therapeutics-neurodegeneration)](/therapeutics)
- [AD Synaptic Repair and Neuroprotection Companies](/companies/ad-synaptic-repair-neuroprotection-companies)
- [AD Neurotrophin and Growth Factor Companies](/companies/ad-neurotrophin-growth-factor-companies)
- [Anti-Amyloid Therapeutics](/therapeutics/anti-amyloid-therapeutics)
References
[Cummings et al., Alzheimer's disease drug development pipeline 2024 (2024)](https://doi.org/10.1002/alz.13856)
[Brimson and Tencomnao, Neuroprotective peptides for neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31346892/)
[Craik et al., The future of peptide-based drugs (2013)](https://doi.org/10.1038/nrd4060)
[Massa et al., Small molecule BDNF mimetics activate TrkB signaling (2010)](https://doi.org/10.1172/JCI41356)